CERO THERAPEUTICS HOLDINGS, INC.

CERO Therapeutics Holdings, Inc. (Nasdaq: CERO) is a clinical-stage biotherapeutics company that came to market through a business combination with Phoenix Biotech Acquisition Corp, a healthcare-focused special purpose acquisition company sponsored by Phoenix Biotech Sponsor LLC that filed its S-1 registration statement in September 2021 and completed its initial public offering that same year. The combined company focuses on developing chimeric engulfment receptor T-cell, or CER-T, therapies targeting hematologic malignancies and solid tumor oncology indications. Post-merger, the company has traded on Nasdaq under the ticker CERO. For the full filing history, deal timeline, and current trading data on CERO and hundreds of other SPAC transactions, sign up for SpacDesk at spacdesk.com.